Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved drugs. More than 1500 fusion transcripts have been published to date, but current practices for fusion transcript detection are hampered by high cost and bias. Typically only the top 1-2 commonly observed fusion transcripts are characterized for most samples.

We have developed a next-generation sequencing solution for highly multiplexed fusion transcript analysis. Using this workflow, hundreds of fusion transcripts can be simultaneously tested in fewer than 24 hours.

In this presentation, Dr Normanno will present an Ion AmpliSeqTM method for fusion detection and analysis from non-small cell lung cancer research samples.